XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Balance Sheets - USD ($)
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 1,762,000 $ 55,000
Prepaid expenses 289,000
Deferred offering costs 327,000
Total current assets 2,051,000 382,000
Non-current asset – cash held in Trust Account 202,913,000
Total assets 204,964,000 382,000
Current liabilities:    
Accounts payable (including approximately $75,000 and $0 of offering costs at March 31, 2025 and December 31, 2024, respectively) 97,000
Accrued liabilities (including approximately $0 and $207,000 of offering costs at March 31, 2025 and December 31, 2024, respectively) 89,000 207,000
Total current liabilities 186,000 447,000
Other liabilities:    
Deferred underwriting fee payable 7,044,000
Total liabilities 7,230,000 447,000
Commitments and contingencies
Class A ordinary shares subject to possible redemption; 20,125,000 and 0 shares at $10.08 and $0.00 per share at March 31, 2025 and December 31, 2024, respectively 202,913,000
Shareholders’ deficit:    
Preferred stock, $0.0001 par value; 1,000,000 authorized shares; none issued or outstanding at March 31, 2025 and December 31, 2024
Additional paid-in capital 24,000
Accumulated deficit (5,180,000) (90,000)
Total shareholders’ deficit (5,179,000) (65,000)
Total liabilities, Class A ordinary shares subject to possible redemption and shareholders’ deficit 204,964,000 382,000
Class A Ordinary Shares    
Other liabilities:    
Class A ordinary shares subject to possible redemption; 20,125,000 and 0 shares at $10.08 and $0.00 per share at March 31, 2025 and December 31, 2024, respectively 202,913,000  
Shareholders’ deficit:    
Ordinary shares, value
Class B Ordinary Shares    
Shareholders’ deficit:    
Ordinary shares, value [1] 1,000 1,000
Related Party    
Current liabilities:    
Promissory note – related party $ 240,000
[1] Included up to 874,912 Class B ordinary shares subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters (see Note 8).